

Supplementary Table 3: Severe subgroup: Statistical Analysis of Primary and Secondary outcomes.

		Severe				
Parameters		C3 Group	Non C3 Group	Odds Ratio (95% CI)	Significance	
Sample Size (n)		15	15			
Sex	Male	7 (46.7%)	11 (73.3%)			
	Female	8 (53.3%)	4 (26.7%)			
Risk Factor	Age >60	7 (46.7%)	5 (33.3%)	1.75 (0.40, 7.66)	Not Significant	
	Unilateral pneumonia	0 (0.0%)	1 (6.7%)	Not Applicable		
	Bilateral pneumonia	15 (100.0%)	14 (93.3%)	Not Applicable		
	Fever	12 (80.0%)	9 (60.0%)	2.67 (0.52, 13.66)	Not Significant	
	Cold	5 (33.3%)	3 (20.0%)	2.00 (0.38, 10.51)	Not Significant	
	Cough	11 (73.3%)	11 (73.3%)	1.00 (0.20, 5.05)	Not Significant	
	Sore throat	6 (40.0%)	1 (6.7%)	9.33 (0.96, 90.94)	Not Significant	
	Sneezing	1 (6.7%)	0 (0.0%)	Not Applicable		
	Runny nose	1 (6.7%)	0 (0.0%)	Not Applicable		
	Shortness of breath	6 (40.0%)	12 (80.0%)	0.17 (0.03, 0.85)	Significant	
	Headache	0 (0.0%)	1 (6.7%)	Not Applicable		
	Diarrhoea	1 (6.7%)	0 (0.0%)	Not Applicable		
	Myalgia	3 (20.0%)	5 (33.3%)	0.50 (0.10, 2.63)	Not Significant	
	Fatigue	3 (20.0%)	2 (13.3%)	1.63 (0.23, 11.46)	Not Significant	
	Loss of taste	0 (0.0%)	0 (0.0%)	Not Applicable		
	Symptoms<6d	11 (73.3%)	11 (73.3%)	1.00 (0.20, 5.05)	Not Significant	
	Symptoms>6d	3 (20.0%)	4 (26.7%)	0.69 (0.12, 3.79)	Not Significant	
PO2	Patient showed red flag signs	Yes	15 (100.0%)	15 (100.0%)	Not Applicable	
		No	0 (0.0%)	0 (0.0%)	Not Applicable	
PO3	Patient maintained SpO2 above 94% on room air throughout the stay	Yes	0 (0.0%)	0 (0.0%)	Not Applicable	
		No	14 (93.3%)	15 (100.0%)	Not Applicable	
PO4	Number of days patient could not maintain SpO2 above 94% on room air	No	0 (0.0%)	15 (100.0%)	Not Applicable	
PO5	Patient required Oxygen therapy	Yes	13 (86.7%)	15 (100.0%)	Not Applicable	
		No	2 (13.3%)	0 (0.0%)	Not Applicable	
PO7	Patient required Oxygen therapy with high flow nasal cannula (HFNC)	Yes	2 (13.3%)	11 (73.3%)	0.06 (0.01, 0.37)	Significant
		No	12 (80.0%)	4 (26.7%)	11.00 (2.00, 60.57)	Significant
PO8	Patient failed to maintain SpO2 more than 88 % despite of oxygenation	Yes	3 (20.0%)	8 (53.3%)	0.22 (0.04, 1.11)	Not Significant
		No	12 (80.0%)	7 (46.7%)	4.57 (0.90, 23.14)	Not Significant
PO9	intubation	Yes	1 (6.7%)	1 (6.7%)	1.00 (0.06, 17.62)	Not Significant
		No	9 (60.0%)	11 (73.3%)	0.55 (0.12, 2.55)	Not Significant
	mechanical ventilation (noninvasive / invasive)	MV-NI	1 (6.7%)	6 (40.0%)	0.11 (0.01, 1.04)	Not Significant
		MV-I	1 (6.7%)	0 (0.0%)	Not Applicable	
PO10	CRP rise		14 (93.3%)	15 (100.0%)	Not Applicable	
	CRP decline		0 (0.0%)	0 (0.0%)	Not Applicable	
	CRP approximately same		1 (6.7%)	0 (0.0%)	Not Applicable	
	D-Dimer rise		12 (80.0%)	15 (100.0%)	Not Applicable	
	D-Dimer decline		0 (0.0%)	0 (0.0%)	Not Applicable	
	D-Dimer approximately same		1 (6.7%)	0 (0.0%)	Not Applicable	
	N/L>3.5		9 (60.7%)	9 (60.0%)	1.00 (0.23, 4.31)	Not Significant
N/L<3.5		4 (26.7%)	5 (33.3%)	0.73 (0.15, 3.49)	Not Significant	
PO11	Chest X Ray abnormalities	Yes	15 (100.0%)	15 (100.0%)	Not Applicable	
		No	0 (0.0%)	0 (0.0%)	Not Applicable	
PO12	Patient required COVID CARP protocol	Yes	13 (86.7%)	14 (93.3%)	0.46 (0.04, 5.75)	Not Significant
		No	2 (13.3%)	1 (6.7%)	2.15 (0.17, 26.67)	Not Significant
PO13	Patient required LMW Heparin	Yes	12 (80.0%)	13 (86.7%)	0.62 (0.09, 4.34)	Not Significant
		No	3 (20.0%)	2 (13.3%)	1.63 (0.23, 11.46)	Not Significant
PO14	Patient required Remdesivir	Yes	13 (86.7%)	15 (100.0%)	Not Applicable	
		No	2 (13.3%)	0 (0.0%)	Not Applicable	
PO15	Patient required cytokine storm treatment eg. Tocilizumab	Yes	2 (13.3%)	4 (26.7%)	0.42 (0.06, 2.77)	Not Significant
		No	13 (86.7%)	11 (73.3%)	2.36 (0.36, 15.46)	Not Significant
SO2	Duration of hospitalisation	<10 days	12 (80.0%)	5 (33.3%)	8.00 (1.52, 42.04)	Significant
		10-14 day	2 (13.3%)	4 (26.7%)	0.42 (0.06, 2.77)	Not Significant
		>14days	1 (6.7%)	6 (40.0%)	0.11 (0.01, 1.04)	Not Significant
SO3	Thromboembolic events	Yes	0 (0.0%)	2 (13.3%)	Not Applicable	
		No	14 (93.3%)	13 (86.7%)	2.15 (0.17, 26.67)	Not Significant
SO4	Pulmonary fibrosis	Yes	2 (13.3%)	14 (93.3%)	0.01 (0.00, 0.14)	Significant
		No	13 (86.7%)	1 (6.7%)	91.00 (7.35, 1126.95)	Significant
SO4	Death related to SARS CoV2 and causes of mortality	Yes	2 (13.3%)	5 (33.3%)	0.31 (0.05, 1.93)	Not Significant
		No	13 (86.7%)	8 (53.3%)	5.69 (0.94, 34.46)	Not Significant
ADR1	Nausea, Vomiting, Abdominal discomfort	Yes	0 (0.0%)	0 (0.0%)	Not Applicable	
		No	15 (100.0%)	15 (100.0%)	Not Applicable	
ADR2	Skin Rash	Yes	0 (0.0%)	0 (0.0%)	Not Applicable	
		No	15 (100.0%)	15 (100.0%)	Not Applicable	
ADR3	Burning micturition	Yes	1 (6.7%)	0 (0.0%)	Not Applicable	
		No	14 (93.3%)	15 (100.0%)	Not Applicable	
ADR4	Excessive bleeding	Yes	0 (0.0%)	0 (0.0%)	Not Applicable	
		No	15 (100.0%)	15 (100.0%)	Not Applicable	

PO - Primary Outcome; SO - Secondary Outcome; ADR - Adverse drug reaction

If 95% confidence interval for odds ratio contains value 1, then the parameter is not significant at 5% level.